Eicosanoids and cardiac arrhythmias

J. Parratt, C. L. Wainwright, S. J. Coker, I. J. Zeitlin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Arachidonic acid breakdown occurs very soon after the onset of myocardial ischaemia with the liberation of products of the cyclooxygenase pathway. A great deal of research has clarified the role of some of these products in modulating the severity of ischaemia (and reperfusion)-induced arrhythmias and this research has recently been reviewed (Parratt 1987, 1988; Parratt et al. 1987). In summary, it appears that these products are an important biochemical determinant of arrhythmia severity. Some substances probably act as protective 'endogenous antiarrhythmic' agents; the release of others seem to intensify arrhythmia severity. It is the balance of release of these substances that appears to be important. One approach therefore to effective antiarrhythmic therapy might be to alter the balance of eicosanoid release in favour of these protective 'endogenous antiarrhythmic' agents, a concept first discussed by Werner Forster (Forster 1976). The purpose of this present short review is to summarise the available experimental evidence for such an approach. Most of this evidence is pharmacological. A more detailed discussion will be found in the articles referred to above.

Original languageEnglish
JournalBiomedica Biochimica Acta
Volume47
Issue number10-11
Publication statusPublished - 1988

Fingerprint

Eicosanoids
Cardiac Arrhythmias
Prostaglandin-Endoperoxide Synthases
Arachidonic Acid
Research
Reperfusion
Myocardial Ischemia
Ischemia
Pharmacology
Therapeutics

ASJC Scopus subject areas

  • Biochemistry

Cite this

Parratt, J., Wainwright, C. L., Coker, S. J., & Zeitlin, I. J. (1988). Eicosanoids and cardiac arrhythmias. Biomedica Biochimica Acta, 47(10-11).

Eicosanoids and cardiac arrhythmias. / Parratt, J.; Wainwright, C. L.; Coker, S. J.; Zeitlin, I. J.

In: Biomedica Biochimica Acta, Vol. 47, No. 10-11, 1988.

Research output: Contribution to journalArticle

Parratt, J, Wainwright, CL, Coker, SJ & Zeitlin, IJ 1988, 'Eicosanoids and cardiac arrhythmias', Biomedica Biochimica Acta, vol. 47, no. 10-11.
Parratt J, Wainwright CL, Coker SJ, Zeitlin IJ. Eicosanoids and cardiac arrhythmias. Biomedica Biochimica Acta. 1988;47(10-11).
Parratt, J. ; Wainwright, C. L. ; Coker, S. J. ; Zeitlin, I. J. / Eicosanoids and cardiac arrhythmias. In: Biomedica Biochimica Acta. 1988 ; Vol. 47, No. 10-11.
@article{da6ab25e645640d285730b2e7467ca36,
title = "Eicosanoids and cardiac arrhythmias",
abstract = "Arachidonic acid breakdown occurs very soon after the onset of myocardial ischaemia with the liberation of products of the cyclooxygenase pathway. A great deal of research has clarified the role of some of these products in modulating the severity of ischaemia (and reperfusion)-induced arrhythmias and this research has recently been reviewed (Parratt 1987, 1988; Parratt et al. 1987). In summary, it appears that these products are an important biochemical determinant of arrhythmia severity. Some substances probably act as protective 'endogenous antiarrhythmic' agents; the release of others seem to intensify arrhythmia severity. It is the balance of release of these substances that appears to be important. One approach therefore to effective antiarrhythmic therapy might be to alter the balance of eicosanoid release in favour of these protective 'endogenous antiarrhythmic' agents, a concept first discussed by Werner Forster (Forster 1976). The purpose of this present short review is to summarise the available experimental evidence for such an approach. Most of this evidence is pharmacological. A more detailed discussion will be found in the articles referred to above.",
author = "J. Parratt and Wainwright, {C. L.} and Coker, {S. J.} and Zeitlin, {I. J.}",
year = "1988",
language = "English",
volume = "47",
journal = "Biomedica Biochimica Acta",
issn = "0232-766X",
publisher = "Akademie Verlag GMBH",
number = "10-11",

}

TY - JOUR

T1 - Eicosanoids and cardiac arrhythmias

AU - Parratt, J.

AU - Wainwright, C. L.

AU - Coker, S. J.

AU - Zeitlin, I. J.

PY - 1988

Y1 - 1988

N2 - Arachidonic acid breakdown occurs very soon after the onset of myocardial ischaemia with the liberation of products of the cyclooxygenase pathway. A great deal of research has clarified the role of some of these products in modulating the severity of ischaemia (and reperfusion)-induced arrhythmias and this research has recently been reviewed (Parratt 1987, 1988; Parratt et al. 1987). In summary, it appears that these products are an important biochemical determinant of arrhythmia severity. Some substances probably act as protective 'endogenous antiarrhythmic' agents; the release of others seem to intensify arrhythmia severity. It is the balance of release of these substances that appears to be important. One approach therefore to effective antiarrhythmic therapy might be to alter the balance of eicosanoid release in favour of these protective 'endogenous antiarrhythmic' agents, a concept first discussed by Werner Forster (Forster 1976). The purpose of this present short review is to summarise the available experimental evidence for such an approach. Most of this evidence is pharmacological. A more detailed discussion will be found in the articles referred to above.

AB - Arachidonic acid breakdown occurs very soon after the onset of myocardial ischaemia with the liberation of products of the cyclooxygenase pathway. A great deal of research has clarified the role of some of these products in modulating the severity of ischaemia (and reperfusion)-induced arrhythmias and this research has recently been reviewed (Parratt 1987, 1988; Parratt et al. 1987). In summary, it appears that these products are an important biochemical determinant of arrhythmia severity. Some substances probably act as protective 'endogenous antiarrhythmic' agents; the release of others seem to intensify arrhythmia severity. It is the balance of release of these substances that appears to be important. One approach therefore to effective antiarrhythmic therapy might be to alter the balance of eicosanoid release in favour of these protective 'endogenous antiarrhythmic' agents, a concept first discussed by Werner Forster (Forster 1976). The purpose of this present short review is to summarise the available experimental evidence for such an approach. Most of this evidence is pharmacological. A more detailed discussion will be found in the articles referred to above.

UR - http://www.scopus.com/inward/record.url?scp=0024202958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024202958&partnerID=8YFLogxK

M3 - Article

C2 - 3073759

AN - SCOPUS:0024202958

VL - 47

JO - Biomedica Biochimica Acta

JF - Biomedica Biochimica Acta

SN - 0232-766X

IS - 10-11

ER -